VTT Technology 342: the 3Rd Conference of the International
Total Page:16
File Type:pdf, Size:1020Kb
NOL CH OG E Y T • • R E E C S N E E The 3rd Conference of the International Society for A I 342 R VTT TECHNOLOGY C C Plant Molecular Farming S H • S H N June 11-13, 2018: Book of abstracts 3 4 2 I G O I H S L I I V G • H S T T he 3rd C o nference of the Internatio nal... The 3rd Conference of the International Society for Plant Molecular Farming June 11-13, 2018: Book of abstracts ISBN 978-951-38-8674-5 (URL: http://www.vttresearch.com/impact/publications) ISSN-L 2242-1211 ISSN 2242-122X (Online) Kirsi-Marja Oksman | Anneli Ritala | Heiko Rischer | http://urn.fi/URN:ISBN:978-951-38-8674-5 Suvi Häkkinen | Jussi Joensuu | Päivi Vahala (Eds.) VTT TECHNOLOGY 342 The 3rd Conference of the International Society for Plant Molecular Farming June 11-13, 2018: Book of abstracts Editors: Kirsi-Marja Oksman Anneli Ritala Heiko Rischer Suvi Häkkinen Jussi Joensuu Päivi Vahala VTT Technical Research Centre of Finland Ltd ISBN 978-951-38-8674-5 (URL: http://www.vttresearch.com/impact/publications) VTT Technology 342 ISSN-L 2242-1211 ISSN 2242-122X (Online) http://urn.fi/URN:ISBN:978-951-38-8674-5 Copyright © VTT 2018 JULKAISIJA – UTGIVARE – PUBLISHER Teknologian tutkimuskeskus VTT Oy PL 1000 (Tekniikantie 4 A, Espoo) 02044 VTT Puh. 020 722 111, faksi 020 722 7001 Teknologiska forskningscentralen VTT Ab PB 1000 (Teknikvägen 4 A, Esbo) FI-02044 VTT Tfn +358 20 722 111, telefax +358 20 722 7001 VTT Technical Research Centre of Finland Ltd P.O. Box 1000 (Tekniikantie 4 A, Espoo) FI-02044 VTT, Finland Tel. +358 20 722 111, fax +358 20 722 7001 Cover image: Maria Teresa Capell Congress Sponsors Conference Sponsors The congress organizers and the International Society of Plant Molecular Farming would like to thank warmly all the sponsors for their valuable contributions. 1 2 Table of Contents Table of Contents Conference Sponsors .......................................................................................................... 1 Table of Contents ................................................................................................................ 3 Welcome to Helsinki .......................................................................................................... 11 Organizing Committee ....................................................................................................... 12 From the Organizing Committee ........................................................................................ 13 Keynote Speakers ............................................................................................................. 15 Social Events ..................................................................................................................... 21 Useful Information of Helsinki ............................................................................................ 23 Scientific Programme ......................................................................................................... 27 Video presenting the biodiversity of Finnish nature ........................................................... 35 Eija Lehmuskallio SESSION 1 Keynote: Plant biotechnology beyond genome era in the dawn of synthetic biology ........ 41 Kirsi-Marja Oksman-Caldentey Manufacturing plant based vaccines “Rift Valley Fever Virus – A case study” ................... 43 Kellner F, Holton N, Cater P, Charlton S, Dowall S A triple combination microbicide against HIV-1 expressed in rice ...................................... 45 Capell T, Vamvaka E, Farré G, Molinos-Albert LM, Evans A, Canela-Xandri A, Twyman RM, Carrillo J, Ordóñez RA, Shattock R, O’Keefe BR, Clotet B, Blanco J, Christou P Modulation of sesquiterpene biosynthesis in khat (Catha edulis) leaves upon harvesting . 47 Lewinsohn E, Bar E, Shotland Y, Hagel JM, Facchini PJ, Dudareva N, Davidovich-Rikanati R Future of disruptive technologies and plant molecular farming .......................................... 49 Reuter L SESSION 2 Keynote: A critical view on the business potential of recombinant protein production in plants ......................................................................................................................... 53 Stefan Schillberg Pharmacokinetics, pharmacodynamics, and safety of Moss-aGalactosidase A in patients with Fabry disease ....................................................................................... 55 Schaaf A, Hennermann JB, Arash-Kaps L, Fekete G, Busch A, Frischmuth, T Immunogenicity of plant-produced porcine circovirus-like particles ................................... 57 Gunter CJ, Regnard GL, Rybicki EP, Hitzeroth II 3 Table of Contents Keynote: Phytochemical genomics: from Arabidopsis to medicinal plants........................ 59 Kazuki Saito Using a synthetic biology approach to develop a novel, easy to use, and open access transient expression system ...................................................................................... 61 Peyret H, Lomonossoff GP Small, Smaller, Nano: New Applications for Potato Virus X in BioNanotechnology ........... 63 Dickmeis C, Röder J, Commandeur U Tailoring Bioactive Natural Products with Glycosyltransferases ........................................ 65 Härtl K, Schwab W SESSION 3 Keynote: From genes to products: A plant biotechnology product portfolio for human and animal health and nutrition ..................................................................... 69 Christou P, Capell T, Zhu C Toward engineering of cannabinoid biosynthesis: In-planta characterization of enzymes involved in the synthesis of THCA and derivatives..................................... 71 Warzecha H, Geissler M, Volk J, Stehle F, Kayser O Supporting explorers on Mars: A biomanufacturing solution for producing biologics during deep space exploration .................................................................................. 73 Nandi S, Karuppanan K, McNulty M, McDonald KA Keynote: On-demand gene expression in plants: New frontiers set by the new synthetic expression system ...................................................................................... 75 Dominik Mojzita Recombinant human osteopontin expressed in Nicotiana benthamiana stimulates osteogenesis related genes in human periodontal ligament cells .............................. 77 Rattanapisit, K, Abdulheem S, Chaikeawkaew D, Kubera A, Mason HS, Ma JKC, Pavasant P, Phoolcharoen W Plant somatic embryo cultures are a profitable source of compounds with skin rejuvenating activity............................................................................................ 79 Barbulova A, Sena LM, Apone F, Colucci MG Combinatorial design of modular and programmable transcriptional regulators in plants .. 81 Selma García S, Bernabé Orts J, Ajenjo Bauzá M, Diego Martin B, Vazquez Vilar M, Granell A and Orzaez D Molecular Farming 6.0: Hexa-mutant Nicotiana benthamiana plants lacking plant plant- specific N-glycans for transient expression ............................................................... 83 Jansing J, Sack M, Augustine SM, Fischer R, Bortesi L Keynote: Genome editing: challenging our views and interpretation of the current regulatory systems .................................................................................................... 85 Joachim Schiemann SESSION 4 Keynote: Development of the next generation influenza vaccine ..................................... 89 Marc-André D’Aoust Genome editing of Nicotiona tabacum suspension cells by a multiplex CRISPR/Cas9 strategy results in humanized pharmaceutical glycoproteins without plant specific glycans .................................................................................... 91 Mercx S, Smargiasso N, Chaumont F, De Pauw E, Boutry M, Navarre C 4 Table of Contents Colour bio-factories: scale-up production of anthocyanins in plant cell cultures ................ 93 Appelhagen I, Wulff-Vester AK, Hvoslef-Eide AK, Russell J, Oertel A, Martens S, Mock H-P, Martin C, Matros A pH gradient mitigation in the leaf cell secretory pathway – One goal, several effects ........ 95 Jutras PV, Goulet MC, Lavoie PO, Tardif R, Hamel LP, D’Aoust MA, Sainsbury F, Michaud D Keynote: Natural products based molecules for target and drug discovery in pharmaceutical research ........................................................................................... 97 Frank Petersen Prolonging serum half-life of plant-made anti-HIV broadly neutralising antibodies (bNAbs) by improving binding to human neonatal Fc receptor (hFcRn) and reducing binding to human macrophage receptor (hMR) ......................................................................... 99 Teh AYH., Stelter S, van Dolleweerd C, Ma JKC Production of secondary metabolites with plant cell cultures from an eco-sustainable view ............................................................................................... 101 Ullish DA, Sankar-Thomas YD, Selge T, Ellert C, Pump M, Leibold T, Schütte K, Gorr G Developing an IgA biobetter antibody against E. coli O157:H7 with enhanced stability by rational design of a bovine Fc chain ...................................................... 103 Chin-Fatt A, Menassa R SESSION 5 Keynote: A multi-omics approach to harness tobacco biochemistry ............................... 107 Jennifer Bromley Recombinant production of the toxic anti-cancer lectin viscumin in tobacco plants and microbial cells. A comparative analysis of yield, process costs and toxicity ............ 109 Gengenbach BB, Keil LL, Opdensteinen P, Müschen CR, Buyel JF Plant-made antimicrobial